MIF and chronic kidney disease: It is an established fact that patients with chronic kidney disease exhibit increased platelet activation, and an attenuated response to dual antiplatelet therapy compared with patients without renal insufficiency.[9] Since we did not assess any parameters of platelet activation or analyzed platelet MIF content before and after HD, these data must be interpreted against this limitation of the study.